62968-37-0

Basic information

• Product Name: 4-(2-CHLORO-4-PYRIMIDINYL)MORPHOLINE
• Synonyms: 4-(2-CHLORO-4-PYRIMIDINYL)MORPHOLINE;4-(2-CHLORO-PYRIMIDIN-4-YL)-MORPHOLINE;4-(2-Chloropyrimidin-4-yl)
• CAS NO: 62968-37-0
• Molecular Formula: C₈H₁₀ClN₃O
• Molecular Weight: 199.64
• Product Categories: Halides;Pyrazines, Pyrimidines & Pyridazines;Pyrazines, Pyrimidines & Pyridazines
• Mol File: 62968-37-0.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 387.56 °C at 760 mmHg
• Flash Point: 188.19 °C
• Appearance: /
• Density: 1.321 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-(2-CHLORO-4-PYRIMIDINYL)MORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-CHLORO-4-PYRIMIDINYL)MORPHOLINE(62968-37-0)
• EPA Substance Registry System: 4-(2-CHLORO-4-PYRIMIDINYL)MORPHOLINE(62968-37-0)

Safety Data

• Hazardous Substances Data: 62968-37-0(Hazardous Substances Data)

Usage

General Description

4-(2-Chloro-4-pyrimidinyl)morpholine is a chemical compound with the molecular formula C7H10ClN3O. It is a heterocyclic organic compound that contains a morpholine ring and a chloropyrimidine ring. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It has also been studied for its potential use as an antiviral and antitumor agent. In addition, 4-(2-Chloro-4-pyrimidinyl)morpholine is known to have moderate toxicity, and caution should be taken when handling and using this compound.

InChI:InChI=1/C8H10ClN3O/c9-8-10-2-1-7(11-8)12-3-5-13-6-4-12/h1-2H,3-6H2

Upstream product

• 110-91-8 morpholine 
• 3934-20-1 2,6-Dichloropyrimidine 

Downstream Products

• 1256757-70-6 1-ethyl-3-(4-(4-morpholinopyrimidin-2-yl)phenyl)urea 
• 1620098-31-8 1-methyl-3-(3-{[4-(morpholin-4-yl)pyrimidin-2-yl]oxy}phenyl)-1H-pyrrolo[3,2-b]quinoline 
• 1351933-97-5 4-(2-(1-tosyl-1H-pyrrol-2-yl)pyrimidin-4-yl)morpholine 
• 1351933-79-3 4-(2-(4-(benzyloxy)phenyl)pyrimidin-4-yl)morpholine 
• 908141-95-7 4-(2-hydrazinylpyrimidin-4-yl)morpholine 

Relevant articles and documents

Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer

The development of inhibitors targeting the PI3K-Akt-mTOR signaling pathway has been greatly hindered by the on-target AEs, such as hyperglycemia and hepatotoxicities. In this study, a series of diaryl urea derivatives has been designed and synthesized based on clinical candidate gedatolisib (6aa), and most of the newly synthesized derivatives showed kinase inhibitory and antiproliferative activities within nanomolar and submicromolar level, respectively. The terminal l-prolineamide substituted derivative 6 ab showed 8.6-fold more potent PI3Kα inhibitory activity (0.7 nM) and 4.6-fold more potent antiproliferative effect against HCT116 cell lines (0.11 μM) compared with control 6aa. The potential antitumor mechanism and efficacy of 6 ab in HCT116 xenograft models have also been evaluated, and found 6 ab showed comparable in vivo antitumor activity with 6aa. The safety investigations revealed that compound 6 ab exhibited more safer profiles in the selectivity of liver cells (selectivity index: >6.6 vs 1.85) and blood glucose regulation than 6aa. In addition, the in vitro stability assays also indicated our developed compound 6 ab possessed good metabolic stabilities.

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Discovery of 3-Oxabicyclo[4.1.0]heptane, a non-nitrogen containing morpholine isostere, and its application in novel inhibitors of the PI3K-AKT-mTOR Pathway

4-(Pyrimidin-4-yl)morpholines are privileged pharmacophores for PI3K and PIKKs inhibition by virtue of the morpholine oxygen, both forming the key hydrogen bonding interaction and conveying selectivity over the broader kinome. Key to the morpholine utility as a kinase hinge binder is its ability to adopt a coplanar conformation with an adjacent aromatic core favored by the morpholine nitrogen nonbonding pair of electrons interacting with the electron deficient pyrimidine Π-system. Few selective morpholine replacements have been identified to date. Herein we describe the discovery of a potent non-nitrogen containing morpholine isostere with the ability to mimic this conformation and its application in a potent selective dual inhibitor of mTORC1 and mTORC2 (29b).